Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Predicting FIX Activity in Prophylaxis Patients Using Recombinant FIX Fc Fusion Protein for Treatment of Bleeding Episodes

Jerry S Powell, MD, Margareth Ozelo, MD PhD, Margaret V. Ragni, MD MPH, John Pasi, MBChB, PhD FRCP, FRCPath, David J. Perry, MD PhD FRCP, FRCPath, Ying Zhu, MPH, Baisong Mei, MD PhD, Glenn F Pierce, MD PhD, Lian Li, PhD, Brian Robinson, MD

Blood (2014) 124 (21): 2842.

https://doi.org/10.1182/blood.V124.21.2842.2842

Published: 2014

Journal Articles

Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously-Treated Children with Severe Hemophilia a (Kids-ALONG)

Guy Young, MD, Johnny N. Mahlangu, MBBCh, MMed, FCPath, Roshni Kulkarni, MD, Beatrice Nolan, MB, MRCPI, FRCPATH, Raina Liesner, MA MBBChir MDFRCP FRCPath MRCPCH, John Pasi, MBChB, PhD FRCP, FRCPath, Christopher Barnes, MB BS, Srividya Neelakantan, PhD, Giulia Gambino, MSc, Lynda M Cristiano, MD, Christopher Barnowski, MD, Glenn F Pierce, MD PhD, Geoffrey A. Allen, MD

Blood (2014) 124 (21): 1494.

https://doi.org/10.1182/blood.V124.21.1494.1494

Published: 2014

Journal Articles

Predicting FVIII Activity in Patients Who Use Recombinant FVIII Fc Fusion Protein for Prophylaxis and Treatment of Bleeding Episodes

Doris V. Quon, MD PhD, Johnny N. Mahlangu, MBBCh, MMed, FCPath, Amy D Shapiro, John Pasi, MBChB, PhD FRCP, FRCPath, Ying Zhu, MPH, Glenn F Pierce, MD PhD, Lian Li, PhD, Geoffrey Allen, MD

Blood (2014) 124 (21): 1522.

https://doi.org/10.1182/blood.V124.21.1522.1522

Published: 2014

Journal Articles

The Bleeding Tendency In Relation To Predicted FVIII Activity Levels In Severe Hemophilia A Patients Treated With Recombinant Factor VIII Fc Fusion Protein

John Pasi, MBChB, PhD, FRCP, FRCPath, James Potts, Ph.D, MPH, Shuanglian Li, Ph.D., Ping Wang, Ph.D., Sarah Kulke, M.D., Glenn F Pierce, MD, PhD, Haiyan Jiang, PhD

Blood (2013) 122 (21): 3590.

https://doi.org/10.1182/blood.V122.21.3590.3590

Published: 2013

Journal Articles

Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study

Amy Shapiro, MD, John Pasi, MBChB, PhD, FRCP, FRCPath, Johnny Mahlangu, MD, David J. Perry, MD, PhD, FRCP, FRCPath, Jerry S Powell, MD, Margaret V. Ragni, MD, MPH, Leonard A. Valentino, MD, FAAP, Margareth Ozelo, MD, PhD, Karen Nugent, MSc, Shuanglian Li, MD, PhD, Aoife Brennan, MB, BCh, BAO, MMSC, Glenn F Pierce, MD, PhD, Geoffrey Allen, MD

Blood (2013) 122 (21): 2350.

https://doi.org/10.1182/blood.V122.21.2350.2350

Published: 2013

Journal Articles

A Two Centre Experience Of Use Of a Dual Virally Inactivated FVIII/VWF Product (Wilate®) In Patients With Von Willebrand Disease

Paul A Batty, MBBS, Kate Khair, PhD, Renu Riat, MBBS, Yun-Han Chen, MBBS, Louise Bowles, Daniel P Hart, MBChB, MRCP, FRCPath, PhD, Ri Liesner, MA MBBChir MD FRCP FRCPath MRCPCH, Sean Platton, Clive Burgess, John Pasi, MBChB, PhD, FRCP, FRCPath

Blood (2013) 122 (21): 1112.

https://doi.org/10.1182/blood.V122.21.1112.1112

Published: 2013

Journal Articles

Adeno-Associated Viral Vector Mediated Gene Transfer for Hemophilia B

Blood (2011) 118 (21): 5.

https://doi.org/10.1182/blood.V118.21.5.5

Published: 2011

NARROW

Predicting FIX Activity in Prophylaxis Patients Using Recombinant FIX Fc Fusion Protein for Treatment of Bleeding Episodes

Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously-Treated Children with Severe Hemophilia a (Kids-ALONG)

Predicting FVIII Activity in Patients Who Use Recombinant FVIII Fc Fusion Protein for Prophylaxis and Treatment of Bleeding Episodes

The Bleeding Tendency In Relation To Predicted FVIII Activity Levels In Severe Hemophilia A Patients Treated With Recombinant Factor VIII Fc Fusion Protein

Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study

A Two Centre Experience Of Use Of a Dual Virally Inactivated FVIII/VWF Product (Wilate®) In Patients With Von Willebrand Disease

Adeno-Associated Viral Vector Mediated Gene Transfer for Hemophilia B

Email alerts

ASH Publications

American Society of Hematology

Predicting FIX Activity in Prophylaxis Patients Using Recombinant FIX Fc Fusion Protein for Treatment of Bleeding Episodes

Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously-Treated Children with Severe Hemophilia a (Kids-ALONG)

Predicting FVIII Activity in Patients Who Use Recombinant FVIII Fc Fusion Protein for Prophylaxis and Treatment of Bleeding Episodes

The Bleeding Tendency In Relation To Predicted FVIII Activity Levels In Severe Hemophilia A Patients Treated With Recombinant Factor VIII Fc Fusion Protein

Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study

A Two Centre Experience Of Use Of a Dual Virally Inactivated FVIII/VWF Product (Wilate®) In Patients With Von Willebrand Disease

Adeno-Associated Viral Vector Mediated Gene Transfer for Hemophilia B

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only